Prime Medicine’s (PRME) “Buy” Rating Reaffirmed at Chardan Capital
Chardan Capital reaffirmed their buy rating on shares of Prime Medicine (NYSE:PRME – Free Report) in a research note released on Monday morning,Benzinga reports. The firm currently has a $15.00 target price on the stock. Other equities analysts have also recently issued reports about the company. Guggenheim reiterated a “buy” rating and issued a $18.00 […]
Chardan Capital reaffirmed their buy rating on shares of Prime Medicine (NYSE:PRME – Free Report) in a research note released on Monday morning,Benzinga reports. The firm currently has a $15.00 target price on the stock. Other equities analysts have also recently issued reports about the company. Guggenheim reiterated a “buy” rating and issued a $18.00 […]
